Equal Partner

Our Alliance with Pfizer

In November 2014, Pfizer and our company entered into a global strategic alliance that enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab*, an investigational anti-PD-L1 antibody initially discovered and developed by our company .

The alliance between Pfizer and our company is an alliance of equal partners. Thus, in the design of announcements, presentations, and publications, neither partner should visually dominate.

  • For joint materials, a neutral design with the appropriate logos in the same size and with the same prominence is used. In general, it is recommended that our Alliance with Pfizer materials utilize a combination of Pfizer Blue and “implementer’s choice” for our company’s color, choosing from our color palette.
  • The Pfizer logo is always positioned right of our EMD Serono logo.
  • The logos are never stacked and there always is a defined minimum spacing between them (here: Pfizer logo vertically oriented)

In the case of similar scenarios, please get in touch with branding@emdgroup.com for further guidance.

* Avelumab is the proposed nonproprietary name for the anti-PD-L1 monoclonal antibody (MSB0010718C).


For general information on our brand design we advise you to have a look at our design basics first. For more guidance please contact branding@emdgroup.com.


The use of our company as reference by third parties.

Learn more


    Our logos are the heart of our brand. They should always be displayed as prominently as possible.

    Learn more

    Science is colorful and we are committed to a colorful future. This is also reflected in our brand.

    Learn more

    Communication is key. We speak with one voice and tell our stories across all channels.

    Learn more